Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the ‘age of remission’?

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

(2010) Shigeru Kotake et al.   JOURNAL OF BONE AND MINERAL RESEARCH

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Association of the HLA–DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis

(2008) Tracey M. Farragher et al.   ARTHRITIS AND RHEUMATISM

Lung disease in rheumatoid arthritis

(2008) Carlotta Nannini et al.   CURRENT OPINION IN RHEUMATOLOGY

The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis

(2008) Yoshiyuki Ohsugi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Role of Interleukin-6 in the Anemia of Chronic Disease

(2008) Dominic S.C. Raj   SEMINARS IN ARTHRITIS AND RHEUMATISM